Paul A. Stone - Aug 29, 2023 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role: Chief Financial Officer
Signature: /s/ Jason Throne, as Attorney-in-Fact for Paul A. Stone
Stock symbol: IDYA
Transactions as of: Aug 29, 2023
Transactions value $: -$144,352
Form type: 4
Date filed: 8/31/2023, 05:49 PM
Previous filing: Aug 23, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IDYA	Common Stock	Sale	-$144K	-5K	-34.96%	$28.87	9.3K	Aug 29, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.
F2	This transaction was executed in multiple trades in prices ranging from $28.83 to $29.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Content

The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.

This transaction was executed in multiple trades in prices ranging from $28.83 to $29.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.